8. The transdermal therapeutic system according to claim 7, wherein the active agent is selected from the group consisting of sexual hormones, a combination of sexual hormones, nitroglycerine, scopolamine, nicotine, lidocaine, diphenylhydraminhydrochloride, salbutomol and fluorouracil.

9. The transdermal therapeutic system according to claim 8, wherein the sexual hormone is selected from the group consisting of estradiol, norethindronacetate and levonorgestrel.

B2 cancel

10. The transdermal therapeutic system according to claim 7, wherein the paper has a weight of from 9 to 60 g/m^2.

11. The transdermal therapeutic system according to claim 10, wherein the paper has a weight of from 15 to 40 g/m^2.

12. The transdermal therapeutic system according to claim 10, wherein the paper has a weight of from 20 to 35 g/m^2.

13. A process for the manufacture of a transdermal therapeutic system comprising at least one active agent and having a range of variation of the amount of active agent applied being lower than 2%, which comprises applying the active agent by means of a tampon to a support material consisting of paper.

14. The process according to claim 13, wherein the range of variation is lower then 1.2%.--

REMARKS

This invention provides for a transdermal therapy system (TTS) which comprises an active agent depot and a matrix wherein at least either the active agent depot or the matrix comprises a support material which consists of paper. This invention further provides for a